Cardiovascular diseases are the number one cause of death globally.1
Worldwide, over 30% of all deaths are attributable to cardiovascular disease (CVD). The increasing incidence and high cost of care of CVDs demands a global approach to prevention, early detection & treatment, and monitoring of disease progression. Used in conjunction with clinical information, cardiac biomarkers are crucial to support rapid and accurate diagnosis, especially in acute cases where every minute counts.2-5
As market leader in cardiac biomarkers, Roche offers diagnostic tests for heart failure (HF), acute coronary syndrome (ACS), and atrial fibrillation (AF)
A large study of United Kingdom healthcare workers suggests that most people are immune for months after catching COVID-19 for the first time.